RemeGen’s Disitamab Vedotin Shows Positive Trial Results
Company Announcements

RemeGen’s Disitamab Vedotin Shows Positive Trial Results

RemeGen Co. Ltd. Class H (HK:9995) has released an update.

RemeGen Co., Ltd. has announced positive results from their Phase III clinical trial for Disitamab Vedotin, a treatment for HER2-positive advanced breast cancer with liver metastases, meeting its primary endpoint. The Company is preparing to submit a marketing application for the drug, which has already been granted breakthrough therapy designation. Disitamab Vedotin, the first domestically developed anti-HER2 antibody-drug conjugate in China, has previously received conditional approval for other cancer treatments.

For further insights into HK:9995 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App